However, it is crucial to carefully consider various factors, like the specific subtype of carcinoma, the exact nature and dose of the COX-2 inhibitor, the stage of the tumor, and the effectiveness and practicality of combining these inhibitors with other treatments [63]. The gene discussed is PTGS2; the disease is carcinoma.